BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220725
DTEND;VALUE=DATE:20220728
DTSTAMP:20260516T024008
CREATED:20220526T184152Z
LAST-MODIFIED:20220526T184152Z
UID:34241-1658707200-1658966399@www.pharmajournalist.com
SUMMARY:Cell Therapy Potency Assay Summit
DESCRIPTION:Cell Therapy Potency Assay Summit\, taking place from 25-27 of July in Boston\, will bring together professionals working in analytical development\, quality\, regulatory and process development functions. \nJoin your peers to: \n\nBrainstorm best-in-class approaches to overcome variability in QC\nCompare next gen approaches from cytotoxicity to omics\nDevelop reference standards to benchmark across the industry\nCreate an assay with commercialization in mind.\n\nThis summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development. \nYou can view the event guide here: https://ter.li/6a13vg \nSecure your place at the summit here: https://ter.li/zp17ep \nWe are looking forward to welcoming you to Boston this July!
URL:https://www.pharmajournalist.com/event/cell-therapy-potency-assay-summit/
LOCATION:The Bostonion\, 26 North Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T024008
CREATED:20220407T101301Z
LAST-MODIFIED:20220413T091417Z
UID:33748-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Gamma Delta T Therapies Summit
DESCRIPTION:The data has dropped and 2022 has been touted as a monumental year for γδT Therapies \nWith Adicet Bio\, In8Bio\, Gamma Delta Therapeutics\, Lava Therapeutics\, and ImCheck Therapeutics releasing clinical data from engineered and antibody-based γδT Therapy in patients; the race to market for the first allogeneic and solid tumor-targeting γδT Therapy is truly on. \nJoin the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including γδT pioneer\, Adrian Hayday\, and together accelerate the development of effective\, persistent\, globally accessible cell therapy for solid tumors. \nTake a look at the official program here. \nEnhance cytotoxicity\, discover novel targets\, engineer stealth and persistence\, interrogate cell subsets\, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies. \nIndustry experts agree that this year\, the γδT is the cell to know. Ensure you and your team are ahead of the curve and equipped with the need-to-know insights to advance successful therapeutics\, across 2 dedicated tracks covering Discovery\, Process Research\, Preclinical\, and Clinical Development; as well as 3 deep-dive workshops\, and a Gamma Delta 101 Bootcamp.
URL:https://www.pharmajournalist.com/event/3rd-gamma-delta-t-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T024008
CREATED:20220407T101551Z
LAST-MODIFIED:20220413T091500Z
UID:33751-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is the only industry-led forum focused on the therapeutic opportunity of drugs directed against B-cell\, plasma cell\, and T-cell targets in autoimmunity. \n \nSeveral drug approvals for B-cell directed therapies have made waves in autoimmune drug development. As investment and industry momentum increases\, this summit will once again unite the movers and shakers of the B&T cell-mediated autoimmune space with the likes of Pfizer\, Nurix\, Regeneron\, Gossamer Bio\, and more. \nTake a look at the 2022 program here. \nAttending this summit is a unique opportunity to be involved in interactive discussions on: \n\nOvercoming challenges of heterogeneity of disease models and demonstrating B cell activation in tissues\nEmerging therapies including B-cell specific therapies\, tolerizing approaches\, small molecule drugs\, engineered cell immunotherapy\, B&T cell checkpoint targeting\, FcRn inhibition\, as well as PROTAC/degrader approaches\nTherapeutic opportunities across both peripheral and tissue specific autoimmune diseases\nOvercoming clinical challenges of treating B&T cell mediated autoimmune diseases through combinatorial regimens that target T-cell co-stimulation\, leveraging autoantibody signatures to identify patient responders and discussing autoimmune disease biomarkers\n\nAs the space grapples with translational and early clinical drug development challenges\, join this comprehensive forum 80+ key leaders and decision-makers to harness the immune system and conquer B&T cell mediated autoimmune diseases.
URL:https://www.pharmajournalist.com/event/3rd-annual-b-t-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220730
DTSTAMP:20260516T024008
CREATED:20220425T085640Z
LAST-MODIFIED:20220425T085640Z
UID:33898-1658793600-1659139199@www.pharmajournalist.com
SUMMARY:Cytokine-Based Drug Development Summit
DESCRIPTION:The 3rd Cytokine-Based Drug Development Summit has been developed following extensive research to address YOUR biggest challenges in the cytokine field. \nWith 30+ expert speakers\, including the hottest academic researchers and leading figures from the industry\, this 4-day program is your opportunity to gain insight into the latest clinical advancement and have thought provoking discussions around how to overcome the fields greatest drug development challenges. \nWhat can you expect to see? \n\nFurther your understanding of the underlying mechanisms of action\, and T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Ask-Gene Pharma\nOptimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Proviva Therapeutics\nLeverage insights from industry’s leading lights to overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with Equilium\, Cytonus Therapeutics & Cytimmune\nTake a deep dive into preclinical cancer models covering both in vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with Astra Zeneca & Xilio Therapeutics\nUncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies with Alkermes & NeoImmune Tech\n\nGet your copy of the brand-new agenda for the full list of speakers and sessions.
URL:https://www.pharmajournalist.com/event/cytokine-based-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T024008
CREATED:20220509T102858Z
LAST-MODIFIED:20220509T102858Z
UID:34021-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit
DESCRIPTION:Do you want to be part of the largest gathering of mRNA professionals? \nThe 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. \nExpect exclusive data from the movers and shakers in mRNA vaccine and therapy development\, 75+ world-class speakers\, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m \nHere’s a snapshot of the expert speakers you can hear from: \n\n​​​​Kathy Fernando\, VP\, Head of Worldwide Research\, Development and Medical Operations & Head of mRNA Scientific Planning\, Pfizer\nRegis Gervier\, Global Head\, mRNA Center of Excellence\, Sanofi\nRituparna Das\, VP – COVID Vaccines\, Moderna\nHao Chen\, Global Head of Cell & Viral Drug Substance\, GlaxoSmithKline\nJoe Payne\, Founder\, President & CEO\, Arcturus Therapeutics\nPervin Anklesaria\, Deputy Director\, HIV Vaccines & Biologics\, Bill & Melinda Gates Foundation\nManmohan Singh\, SVP – Pharmaceutical Sciences & Delivery Technologies\, Beam Therapeutics\nAkhilesh Bhambhani\, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops\, Ultragenyx\nLiang Shang\, Senior Scientist – Vaccine Analytical\, Merck\nRussell Johnson\, VP – Formulation Research\, RVAC Medicines\nTamar Grossman\, Global Head – RNA & Targeted Therapeutics\, The Janssen Pharmaceutical Companies of Johnson & Johnson\n\nDownload the official brochure to discover why Sanofi\, Ultragenyx\, Beam Therapeutics\, Pfizer\, Moderna\, Merck\, Eli Lilly\, GSK\, and 300+ others have already secured their places.  https://ter.li/yc800m
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T024008
CREATED:20220518T092848Z
LAST-MODIFIED:20220518T092848Z
UID:34131-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:iPSC Manufacturing Summit
DESCRIPTION:With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy\, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing\, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients. \nThis forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products\, with in depth case studies aimed to develop optimal differentiation\, cryopreservation\, and analytical protocol to enhance process development to ensure it is robust\, rapid and repeatable. \nOur 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization\, enhance iPSC product quality\, and integrate successful gene-editing into your manufacturing. \nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/ipsc-manufacturing-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T024008
CREATED:20220526T182248Z
LAST-MODIFIED:20220526T182344Z
UID:34229-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:Targeted Radiopharmaceuticals Summit US (TRP US)
DESCRIPTION:The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months\, with a wave of new investment in light of Lutathera’s extraordinary performance. \nAre you part of a pharmaceutical business aiming to have their Theranostic approved? If so\, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging. \nHear the latest insights\, case studies\, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies. \nTo know more visit: https://ter.li/jtzz4q
URL:https://www.pharmajournalist.com/event/targeted-radiopharmaceuticals-summit-us-trp-us/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR